INBS 10-Q filed 2026-11-10 | Key takeaways
INBS filed its 10-Q; the most relevant disclosure change is expanded Liquidity and going concern: At September 30, 2026, INBS reported $5,929,871 of cash and $4,466,995 of working capital. Management still said the cash would be insufficient to fund the operating plan for at least 12 months and that these conditions raised substantial doubt about the compa. Customer concentration: One customer represented 13.2% of revenue.
Key takeaways
Liquidity and going concern: The company reported $5,929,871 of cash and $4,466,995 of working capital at September 30, 2026, but said cash would be insufficient to fund its operating plan for at least 12 months.
Private placement: The September 2026 offering closed on September 2 and raised approximately $5.0 million before fees and expenses through Series M Pre-Funded Warrants and Series N-1 and N-2 Warrants.
FDA submission: INBS submitted a 510(k) premarket notification on September 9, 2026 seeking clearance for codeine detection; its disclosed Method Comparison Study reported accuracy above 98%, sensitivity above 94% and specificity of 100%.
Reverse split and reporting status: A 1-for-10 reverse stock split became effective December 15, 2025, and the company ceased to qualify as an emerging growth company at June 30, 2026 while remaining a smaller reporting company.
Customer concentration: One customer represented 13.2% of revenue versus 11.7% in the prior-year quarter, implying approximately 41.2% year-over-year growth in revenue attributable to that customer.
Supplier concentration: The largest suppliers represented 25.5% of purchases versus 17.6% in the prior-year quarter.
Contractual obligations: Remaining lease payments totaled $2,887,153, the Australian Government grant repayment was $1,131,147 and clinical-study commitments remained payable at $1,357,742.
Key metrics
Customer concentration
Disclosure changes
- Liquidity and going concern
At September 30, 2026, INBS reported $5,929,871 of cash and $4,466,995 of working capital. Management still said the cash would be insufficient to fund the operating plan for at least 12 months and that these conditions raised substantial doubt about the company's ability to continue as a going concern.
The financing increased liquidity, but management continued to require additional capital to fund operations. - September 2026 Private Placement
The company closed a private placement on September 2, 2026 that generated approximately $5.0 million before fees and expenses. The securities were three warrant series, each covering 2,036,659 shares, and the proceeds were designated for working capital and general corporate purposes.
The offering replenished cash while adding warrants that could dilute shareholders; Series N-2 exercise remains conditional on shareholder approval. - Warrants and dilution
Outstanding warrants increased to 12,045,102 shares at a weighted-average exercise price of $3.64, compared with 3,316,803 common shares outstanding. The filing states that the warrant shares represent more than three times outstanding common shares and that the private-placement shares were registered for resale.
The September private placement materially increased the number of potentially dilutive securities and registered resale shares. - Reverse stock split and filer status
INBS effected a 1-for-10 reverse stock split effective December 15, 2025, with split-adjusted trading beginning December 16. At June 30, 2026, it ceased to qualify as an emerging growth company but remained a smaller reporting company and non-accelerated filer.
All share and per-share data were retroactively adjusted for the reverse split, and loss of emerging-growth-company status reduces certain reporting and governance accommodations. - FDA 510(k) regulatory program
The company submitted its 510(k) premarket notification to the FDA on September 9, 2026, seeking clearance to market the IFP System for codeine detection. The filing also reports completion of precision, usability, interference and method-comparison studies supporting the submission.
The filing discloses a specific FDA submission date and the studies supporting U.S. commercialization while retaining clearance timing as a risk. - Customer concentration
One customer accounted for 13.2% of revenue in the September 2026 quarter, up from 11.7% in the prior-year quarter. Applied to reported revenue, implied customer revenue increased from approximately $130,080 to $183,722.
Single-customer revenue concentration increased by 1.5 percentage points year over year.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow INBS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.